Fund+ Portfolio Company Tubulis to be Acquired by Gilead

Fund+ quote visual Caroline Goddeeris

• Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments

• Tubulis’ next-generation ADC platform includes its clinically validated linker-payload technology

• The acquisition includes Tubulis’ lead asset TUB-040, a NaPi2b-targeting ADC for ovarian cancer and other solid tumors